Your browser doesn't support javascript.
loading
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome.
Begg, Malcolm; Amour, Augustin; Jarvis, Emily; Tang, Teresa; Franco, Sara Santos; Want, Andrew; Beerahee, Misba; Fernando, Disala; Karkera, Yakshitha; Sander, Clare; Southworth, Thomas; Singh, Dave; Clark, Jonathan; Nejentsev, Sergey; Okkenhaug, Klaus; Condliffe, Alison; Chandra, Anita; Cahn, Anthony; Hall, Edward Banham.
Afiliação
  • Begg M; Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, UK. Electronic address: malcolm.5.begg@gsk.com.
  • Amour A; Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, UK.
  • Jarvis E; Clinical Statistics, Development, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, UK.
  • Tang T; Global Medical Safety, Development, GlaxoSmithKline, GSK House, London, UK.
  • Franco SS; Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke's Hospital, Cambridge, UK.
  • Want A; Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke's Hospital, Cambridge, UK.
  • Beerahee M; Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, UK.
  • Fernando D; Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke's Hospital, Cambridge, UK.
  • Karkera Y; Clinical Statistics, Development, GlaxoSmithKline, Prestige Trade Tower, Palace Road, Bangalore, India.
  • Sander C; Addenbrooke's NHS Hospital Trust, Cambridge, UK.
  • Southworth T; Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK; Medicines Evaluation Unit, Manchester University NHS Hospital Trust, Manchester, UK.
  • Singh D; Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK; Medicines Evaluation Unit, Manchester University NHS Hospital Trust, Manchester, UK.
  • Clark J; Biological Chemistry, Babraham Institute, Cambridge, UK.
  • Nejentsev S; Department of Medicine, University of Cambridge, Cambridge, UK; Amsterdam UMC location Vrije Universiteit Amsterdam, Molecular Cell Biology and Immunology, Amsterdam, the Netherlands; Amsterdam Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • Okkenhaug K; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Condliffe A; Department of Infection, Immunity and Cardiovascular Disease, The Medical School, University of Sheffield, Sheffield, UK.
  • Chandra A; Department of Medicine, University of Cambridge, Cambridge, UK; Department of Clinical Immunology, Addenbrooke's Hospital, Cambridge, UK.
  • Cahn A; Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, UK.
  • Hall EB; Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke's Hospital, Cambridge, UK.
Pulm Pharmacol Ther ; 79: 102201, 2023 04.
Article em En | MEDLINE | ID: mdl-36841351
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfatidilinositol 3-Quinases / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfatidilinositol 3-Quinases / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article